PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsTeriparatide
Parathar, Forsteo(teriparatide)
Bonsity, Forsteo, Forteo, Kauliv, Livogiva, Movymia, Parathar, Sondelbay, Teriparatide, Terrosa (teriparatide) is a protein pharmaceutical. Teriparatide was first approved as Parathar on 1987-12-23. It is used to treat postmenopausal osteoporosis in the USA. It has been approved in Europe to treat osteoporosis and postmenopausal osteoporosis. The pharmaceutical is active against parathyroid hormone/parathyroid hormone-related peptide receptor. In addition, it is known to target parathyroid hormone 2 receptor.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
nutritional and metabolic diseasesD009750
Trade Name
FDA
EMA
Bonsity, Forteo, Teriparatide (discontinued: Forteo, Parathar)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Teriparatide
Tradename
Company
Number
Date
Products
BONSITYAlvogenN-211939 RX2019-10-04
1 products
FORTEOEli LillyN-021318 RX2008-06-25
1 products, RLD, RS
Show 1 discontinued
Teriparatide acetate
Tradename
Company
Number
Date
Products
PARATHARSanofiN-019498 DISCN1987-12-23
1 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
bonsityNew Drug Application2025-06-01
forteoNew Drug Application2025-06-03
teriparatideANDA2025-07-14
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
postmenopausal osteoporosisEFO_0003854D015663—
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Teriparatide, Forteo, Lilly
75173342025-03-25DP
ATC Codes
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H05: Calcium homeostasis
— H05A: Parathyroid hormones and analogues
— H05AA: Parathyroid hormones and analogues
— H05AA02: Teriparatide
HCPCS
Code
Description
J3110
Injection, teriparatide, 10 mcg
Clinical
Clinical Trials
195 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
OsteoporosisD010024EFO_0003882M81.0———1—1
Postmenopausal osteoporosisD015663EFO_0003854————1—1
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTeriparatide
INNteriparatide
Description
TERIPARATIDE
Classification
Protein
Drug classpeptides: parathyroid hormone related peptide
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C
Identifiers
PDB—
CAS-ID52232-67-4
RxCUI—
ChEMBL IDCHEMBL525610
ChEBI ID—
PubChem CID16132393
DrugBankDB06285
UNII ID10T9CSU89I (ChemIDplus, GSRS)
Target
Agency Approved
PTH1R
PTH1R
Organism
Homo sapiens
Gene name
PTH1R
Gene synonyms
PTHR, PTHR1
NCBI Gene ID
5745
Protein name
parathyroid hormone/parathyroid hormone-related peptide receptor
Protein synonyms
Parathyroid hormone 1 receptor, parathyroid hormone receptor 1, parathyroid hormone/parathyroid hormone-related protein receptor, PTH/PTHr receptor, PTH/PTHrP type I receptor, PTH1 receptor, seven transmembrane helix receptor
Uniprot ID
Q2M1U3
Mouse ortholog
Pth1r (19228)
parathyroid hormone/parathyroid hormone-related peptide receptor (Q80WU8)
Alternate
PTH2R
PTH2R
Organism
Homo sapiens
Gene name
PTH2R
Gene synonyms
PTHR2
NCBI Gene ID
5746
Protein name
parathyroid hormone 2 receptor
Protein synonyms
parathyroid hormone receptor 2, PTH2 receptor
Uniprot ID
Q8N429
Mouse ortholog
Pth2r (213527)
parathyroid hormone 2 receptor (Q91V95)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Teriparatide – Ligand Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Forteo – Eli Lilly
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Teriparatide
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 9,301 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
128,728 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use